Ischemic stroke (IS) is one of the leading causes of death and neurological disability worldwide. Despite the significant burden of IS, recombinant tissue plasminogen activator (rt-PA/alteplase [Genentech’s Activase, other brands]) is the only pharmacological therapy approved for the (acute) treatment of IS owing to persistent failure of investigational compounds over the past two decades. However, because of strict inclusion criteria and documented safety risks, only a small fraction of diagnosed IS events receive rt-PA. Therefore, a tremendous amount of unmet clinical need remains for alternative treatments that can help avert permanent neurological damage and restore neurological function in post-stroke survivors living with residual impairment.
Geography: United States
Primary Research: 3 KOL interviews in April 2020
Key Companies Covered: Genentech / Roche, Boehringer Ingelheim, Mitsubishi Tanabe Pharma, Biogen, Genervon, Athersys, ZZ Biotech, SanBio, Lumosa Therapeutics, ReNeuron, Stemedica Cell Technologies, NoNO
Key Drugs Covered: rt-PA/alteplase (Activase/Actilyse, other brands), edaravone (Radicut, generics), citicoline (Somazina, generics), tenecteplase, glibenclamide, 3K3A-APC, GM602, MultiStem, SB 623, LT 3001, ReN-001, NA-1
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.